Earnings call transcript: Iress lifts profit outlook in H1 2026 as revenue slows

Iress reported H1 FY2026 cash EBITDA of AUD 62.5m, up 47.1% (constant currency) and cash EBITDA margins expanding by 740 bps to 24.5%, supported by recurring revenue rising 3.4% to 95% of continuing revenue. For FY2026, the company cut revenue guidance to AUD 509m–515m (1%–2% growth) but raised cash EBITDA guidance to AUD 121m–126m (up 21%–26%). The board increased the interim dividend 27% to AUD 0.14/share (fully franked) and reduced leverage to 0.5x, though commentary points to weaker non-recurring revenue and FX (stronger AUD) as offsetting headwinds.

Analysis

The real signal is that earnings power is becoming less cyclical just as the market is still pricing it like a restructuring story. Higher recurring mix, low leverage, and a materially better cash conversion profile should support a multiple reset in the next 1-3 months, but only if investors believe the margin step-up is sustainable after the second-half investment ramp. The risk is that the current run rate is being helped by cost actions and lower capex timing; if revenue does not reaccelerate into 2027, the market will likely cap the rerating at a mid-single-digit EBITDA multiple expansion rather than award a true SaaS-quality premium.

Second-order winners are recurring-revenue software peers with similar customer bases but weaker optics on margins; the market may begin to distinguish “cleaner” platform businesses from project-heavy vendors. That is potentially constructive for sector sentiment around ASX-listed wealth-tech names, while vendors dependent on implementation fees could see slower bookings as clients defer discretionary non-recurring work. The foreign exchange drag is also a reminder that reported growth can remain noisy even when operational momentum improves, so any follow-through will be driven by constant-currency recurring trends rather than headline revenue.

Contrarian view: the consensus may be underestimating how much balance-sheet repair changes optionality here. At 0.5x leverage, management can fund product modernization without stretching the P&L, which lowers downside if execution is merely adequate. What would falsify the thesis is either a miss on the implied 25% exit margin, or a second-half revenue print that shows the recurring base is not strong enough to offset the collapse in project work; in that case this becomes a low-growth, moderately profitable software name rather than a turnaround compounder.

Key Decisions for Investors

• Watchlist: initiate/keep IRE.AX on a pullback only if the stock gives back the post-result momentum and still holds above the prior breakout area; upside case is a 10-15% rerating over 1-3 months if recurring revenue trends remain intact, downside is that a failed 25% exit-margin narrative would likely erase the move quickly.
• Pair trade idea: long IRE.AX / short a higher-execution-risk wealth-tech peer such as BVS.AX for 1-3 months, on the thesis that the market will reward cleaner recurring mix and balance-sheet strength while punishing businesses still more exposed to implementation slippage; stop if Iress loses the margin guide or Bravura shows accelerating bookings.
• Sector alert: add a watch on ASX software/fintech names with heavy project revenue exposure; if clients are delaying non-recurring work across the UK and APAC, that is a leading indicator for softer FY27 pipeline conversion and could pressure names with similar revenue mix over the next 2 quarters.
• Do not chase the dividend headline: treat the higher payout as a confidence signal, not a catalyst. The key entry confirmation is either an upgrade to FY27 revenue guidance or evidence that H2 capex spend is converting into actual recurring sales conversion.